宇順電子(002289.SZ):資產重組事項11月3日上會 當天停牌
格隆匯11月2日丨宇順電子(002289.SZ)公佈,公司擬以發行股份及支付現金方式購買凱旋門控股有限公司、白宜平合計持有的深圳前海首科科技控股有限公司100%股權,並向公司控股股東中植融雲(北京)企業管理有限公司非公開發行股份募集配套資金。
根據中國證監會2021年10月28日公佈的《併購重組委2021年第28次工作會議公吿》,中國證監會上市公司併購重組審核委員會定於2021年11月3日上午9:00召開2021年第28次併購重組委工作會議,審核公司發行股份及支付現金購買深圳前海首科科技控股有限公司100%股權事項。
經公司向深交所申請,公司股票將自11月3日開市起停牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.